Alnylam Pharmaceuticals, Inc.
EXTRAHEPATIC DELIVERY

Last updated:

Abstract:

The invention relates to a method of gene silencing, comprising administering to a cell or a subject in need thereof a therapeutically effective amount of the lipophilic moieties-conjugated double-stranded iRNAs at one or more internal positions on at least one strand, optionally via a linker or carrier.

Status:
Application
Type:

Utility

Filling date:

7 May 2019

Issue date:

28 Apr 2022